170 related articles for article (PubMed ID: 1797154)
1. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. II. Relationships between chemical structure and inhibition of PAF-induced human platelet activation.
Ostermann G; Hofmann B; Kertscher HP; Till U
J Lipid Mediat; 1991; 3(2):225-37. PubMed ID: 1797154
[TBL] [Abstract][Full Text] [Related]
2. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
Ostermann G; Hofmann B; Kertscher HP; Till U
J Lipid Mediat; 1990; 2(1):21-31. PubMed ID: 1966804
[TBL] [Abstract][Full Text] [Related]
3. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
Ostermann G; Hofmann B; Kertscher HP; Till U
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of PAF-induced human platelet responses by newly synthesized ether phospholipids.
Ostermann G; Hofmann B; Kertscher HP; Till U
Thromb Res; 1991 Feb; 61(3):261-9. PubMed ID: 2028445
[TBL] [Abstract][Full Text] [Related]
5. Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets.
Hofmann B; Ostermann G; Kertscher HP; Till U
Thromb Res; 1988 Feb; 49(4):415-23. PubMed ID: 3381200
[TBL] [Abstract][Full Text] [Related]
6. [PAF-antagonists with phospholipid structure. 2. Phospholipids with heteroarene head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationships].
Kertscher HP; Ostermann G
Pharmazie; 1991 Oct; 46(10):708-11. PubMed ID: 1803385
[TBL] [Abstract][Full Text] [Related]
7. Species difference in the specific receptors of platelet activating factor.
Hwang SB; Lam MH
Biochem Pharmacol; 1986 Dec; 35(24):4511-8. PubMed ID: 3024653
[TBL] [Abstract][Full Text] [Related]
8. Species-dependent differences of high affinity [3H]PAF-binding to platelets from humans and pigs and its inhibition by selected antagonists.
Ostermann G; Lorenz A; Hofmann B; Kertscher HP
J Lipid Mediat; 1991 Nov; 4(3):289-98. PubMed ID: 1662546
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PAF-induced tPA release by KO-286011.
Klöcking HP
Ann N Y Acad Sci; 1992 Dec; 667():202-3. PubMed ID: 1309038
[No Abstract] [Full Text] [Related]
10. Comparison of three paf-acether receptor antagonist ginkgolides.
Korth R; Nunez D; Bidault J; Benveniste J
Eur J Pharmacol; 1988 Jul; 152(1-2):101-10. PubMed ID: 2850196
[TBL] [Abstract][Full Text] [Related]
11. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.
Nunez D; Chignard M; Korth R; Le Couedic JP; Norel X; Spinnewyn B; Braquet P; Benveniste J
Eur J Pharmacol; 1986 Apr; 123(2):197-205. PubMed ID: 3086108
[TBL] [Abstract][Full Text] [Related]
12. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds.
Baroggi N; Etienne A; Braquet P
Agents Actions Suppl; 1986; 20():87-97. PubMed ID: 3028108
[TBL] [Abstract][Full Text] [Related]
13. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
[TBL] [Abstract][Full Text] [Related]
14. Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets.
Adnot S; Joseph D; Vargaftig BB
Agents Actions; 1987 Jun; 21(1-2):195-202. PubMed ID: 3115070
[TBL] [Abstract][Full Text] [Related]
15. [PAF-antagonists with a phospholipid structure. 1. Phospholipids with hetero-arene head groups: synthesis, characterization and determination of the action of structural elements].
Kertscher HP; Ostermann G; Findeisen M; Limmer S; Gawrisch K
Pharmazie; 1991 Aug; 46(8):575-9. PubMed ID: 1798710
[TBL] [Abstract][Full Text] [Related]
16. Reversible or irreversible modification of [3H]PAF binding on rabbit platelet membranes differentiates various PAF receptor antagonists.
Domingo MT; Piro F; Broquet C; Auclair E; Chabrier PE; Braquet P
Lipids; 1992 Aug; 27(8):582-6. PubMed ID: 1328798
[TBL] [Abstract][Full Text] [Related]
17. Effect of synthetic phospholipids on platelet aggregation and serotonin release.
Söling U; Eibl H; Nagel GA; Unger C
Lipids; 1987 Nov; 22(11):868-70. PubMed ID: 3444380
[TBL] [Abstract][Full Text] [Related]
18. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis.
Biancone L; Cantaluppi V; Boccellino M; Bussolati B; Del Sorbo L; Conaldi PG; Albini A; Toniolo A; Camussi G
Am J Pathol; 1999 Nov; 155(5):1731-9. PubMed ID: 10550329
[TBL] [Abstract][Full Text] [Related]
19. [Phospholipid thrombocyte activating factor, its analogs and antagonists: prospects of their use in medicine].
Kulikov VI; Muzia GI
Vestn Akad Med Nauk SSSR; 1991; (10):13-7. PubMed ID: 1801455
[TBL] [Abstract][Full Text] [Related]
20. [Platelet-activating factor (PAF) antagonists].
Terasawa M
Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):379-87. PubMed ID: 1850862
[No Abstract] [Full Text] [Related]
[Next] [New Search]
